Formulation Facility I KANDLA UNIT I (GUJARAT, INDIA)
Installed Capacity
|
Dosage form |
Annual Capacity |
|---|---|
|
Tablets |
2062 Million |
|
General Capsules |
325 Million |
|
Sachet |
60 Million |
|
Injectable (Lyo- Vials) |
0.5 Million |
|
Injectable (Liquid Vials) |
1.8 Million |
|
Glass Ampoule |
18 Million |
|
Cream & Ointment |
4 Millions |
Approved by
-
BRAZIL
-
SOUTH AFRICA
-
TANZANIA
-
ZIMBABWE
-
UAE-MOH
-
KENYA
-
UGANDA
-
RUSSIA
-
KAZAKHSTAN
-
EUROPE
-
STATE-GMP WHO-CDSCO
Planned:
-
CANADA
-
MEXICO
-
UKRAINE

Formulation Facility II KANDLA UNIT II (GUJARAT, INDIA)
Installed Capacity
|
Dosage form |
Annual Capcity |
|---|---|
|
Transdermal Patch |
6 Million |
*Capacity as per shift basis
Approved by:
-
BRAZIL
-
AUSTRALIA
-
UAE-MOH
-
STATE-GMP WHO-CDSCO
Planned:
-
RUSSIA
-
EUROPE


Formulation Facility III DEHRADUN (UTTARAKHAND, INDIA)
Installed Capacity
|
Dosage form |
Annual Capacity |
|---|---|
|
Tablets |
3252 Million |
|
General Capsules |
144 Million |
|
Oral Liquid- Syrup |
1.14 Million |
|
Transdermal Patches |
0.98 Million |
|
Glass Vials |
1 Million |
|
Prefilled Syring |
6 Million |
*Capacity as per 3 shift basis
Approved by
-
CANADA
-
EUROPE
-
AUSTRALIA
-
BRAZIL
-
SOUTH AFRICA
-
UKRAINE
-
KENYA
-
UGANDA
-
SWITZERLAND
-
UAE_MOH
-
VIETNAM
-
RUSSIA
-
STATE - GMP WHO-CDSCO
Planned:
-
JAPAN
-
MALAYSIA
-
PHILIPPINES

API Facility IIPITHAMPUR (MADHYA PRADESH, INDIA)
ProductionCapacity (KL) - 60 Tons
Approved by
-
STATE-GMP WHO-CDSCO
Planned:
-
USFDA
-
EUROPE
-
WHO-CDSCO

API Facility I ANKLESHWAR (GUJARAT, INDIA)
Installed Capacity
|
Production |
Capacity (KL) |
|---|---|
|
Plant – I |
3.0KL |
|
Plant – II |
30.0KL |
|
Total |
33 KL (33Tons ) of annual production |
**Capacity as per 3 shift basis
Approved by:
-
USFDA
-
CANADA
-
EUROPE
-
JAPAN
-
BRAZIL
-
STATE-GMP WHO-CDSCO



